Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104471 | 1.00 | NR1H2 (0.30) | NR1H2ALOX5 | |
| SCHEMBL2104467 | 1.00 | NR1H2 (0.30) | NR1H2ALOX5 | |
| SCHEMBL2105244 | 1.00 | NR1H2 (0.30) | NR1H2ALOX5 | |
| SCHEMBL1543505 | 1.00 | NR1H2 (0.30) | NR1H2ALOX5 | |
| SCHEMBL963000 | 0.92 | NR1H2 (0.34) | NR1H2 | |
| SCHEMBL1847732 | 0.86 | NR1H2 (0.37) | NR1H2 | |
| SCHEMBL1847734 | 0.86 | NR1H2 (0.37) | NR1H2 | |
| SCHEMBL482044 | 0.81 | NR1H2 (0.33) | NR1H2 | |
| SCHEMBL482043 | 0.81 | NR1H2 (0.33) | NR1H2 | |
| SCHEMBL343055 | 0.81 | NR1H2 (0.33) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | NR1H2 3102/4885ALOX5 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.